TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03994107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
Study: NCT01272674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: 4 weeks supervised physical exercise training
Study: NCT02782728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS-Plus
Description: Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
Study: NCT03694808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone HD Vaccine
Description: single high dose (HD) intramuscular injection
Study: NCT00002787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous immunoglobulin idiotype-KLH conjugate vaccine
Description: Given SC
Study: NCT02782728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIPS-Basic
Description: Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
Study: NCT02966431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Counseling
Study: NCT00440583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy followed by Zevalin
Description: 6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
Study: NCT03954197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No hormone
Description: No hormonal injection before oocytes retrieval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No hormone
Description: No hormonal injection before oocytes retrieval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
Study: NCT03480854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement
Description: Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
Study: NCT04303156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Single oral dose of 60 mg Islatravir administered in capsule form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Single oral dose of 60 mg Islatravir administered in capsule form
Study: NCT02570568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinlite
Description: Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen-torch Transillumination
Description: Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Venepuncture
Description: This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
Study: NCT01077934

Intervention type: DEVICE
Intervention: near-infrared spectroscopy
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.

Intervention type: DEVICE
Intervention: near-infrared spectroscopy
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
Study: NCT03705442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omni-Biotic 10
Description: All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: loperamide (Seldiar)
Description: All the patients will have access to standard drugs for diarrhoea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide (Seldiar)
Description: All the patients will have access to standard drugs for diarrhoea
Study: NCT04291729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganovo+ritonavir+/-Interferon nebulization
Description: Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
Study: NCT03352778

Intervention type: RADIATION
Intervention: IMRT
Description: 66Gy by intensity-modulated radiotherapy

Intervention type: RADIATION
Intervention: 2DRT
Description: 66Gy by 2-dimensional radiotherapy
Study: NCT02889718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONCERT-CL® station
Description: During cancer surgery (surgery \> 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~* Port B = open loop: Analgesic~* Port A = closed loop: Hypnotic~* Port C = closed loop: Curare

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
Study: NCT04395235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: A multi-item survey was prepared to assess fellow's perception of residency training. The survey was utilized by our group, understanding of patient vascular anatomy, awareness of the changes based on variations, independent decision-making, differential diagnosis, plan on key surgical steps, and preparation for unexpected bleeding. The answers to the questions asked for each case were analyzed to include senior (3 years and over) - junior (1-2 years) residents.Assistants spend 45 minutes in the survey. Data are entered into SPSS 24.0 for statistical analysis. Wilcoxon Signed Ranks Test was used to determine any significant differences in the measurements between the original CT images, 3D rendered images, the 3D model and CT images of the 3D model. Statistical significance was defined as a p value of less than 0.05. Junior assistants stated that they perceived 2D image statistically better than 3D models compared to the senior assistants (Kruskal-Wallis Test).
Study: NCT00002787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02315066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600
Description: Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600 plus PF-05082566
Description: Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04518600 plus PF-05082566
Description: Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
Study: NCT03099629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
Study: NCT01232491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Description: Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary regimen
Description: Subjects receive dietary consultation by a dietician at six occasions during the trial.
Study: NCT00898534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bayer DCA2000+ Hemoglobin A1c analyzer
Description: Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
Study: NCT01095419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: no intervention
Study: NCT01854086

Intervention type: OTHER
Intervention: Questionnaires about compliance and persistence with bisphosphonates treatment
Study: NCT04594915

Intervention type: DRUG
Intervention: Edoxaban
Description: Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).
Study: NCT01293552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: single dose application

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: single dose application

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: single dose application

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: single dose application
Study: NCT03741296

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single stage revision
Description: One-stage exchange hip joint replacement surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage revision
Description: Two-stage exchange hip joint replacement surgery
Study: NCT00553137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluconazole
Description: 750 mg (5 tablets of 150 mg tablets)taken once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluconazole
Description: 150 mg fluconazole tablets once daily for 14 days
Study: NCT01293552

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT02785952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03000387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Active nicotine patch of 21 mg, 14 mg and 7 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine Patch
Description: Active nicotine patch of 21 mg, 14 mg and 7 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Active nicotine patch of 21 mg, 14 mg and 7 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo patches of 21 mg, 14 mg and 7 mg
Study: NCT02043223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A (<3-day postpartum)
Description: Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A (6 wk postpartum)
Description: Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A (<3-day and 6 wk postpartum)
Description: 200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo supplementation, both at \<3-day and 6-wk postpartum.
Study: NCT02074774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntellO2
Description: Automated FiO2 regulator that responds to pulse oximetry measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual control
Description: Standard practice of manually titrating FiO2 as needed.
Study: NCT02420613

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03375905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cNEP
Description: subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
Study: NCT06466928

Intervention type: PROCEDURE
Intervention: Total pancreatectomy
Description: Surgical removal of the entire pancreas

Intervention type: PROCEDURE
Intervention: Total pancreatectomy
Description: Surgical removal of the entire pancreas

Intervention type: PROCEDURE
Intervention: Total pancreatectomy
Description: Surgical removal of the entire pancreas

Intervention type: PROCEDURE
Intervention: Total pancreatectomy
Description: Surgical removal of the entire pancreas
Study: NCT00252122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine. 0.2 mg/kg, intravenously
Study: NCT03172611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
Study: NCT03297307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presurgical Counseling
Description: Children will attend the presurgical counseling visits with their mother
Study: NCT03734081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODC system (type 1 capsule)
Description: ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODC system (type 2 capsule)
Description: ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODC system (type 2 capsule)
Description: ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
Study: NCT02159326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
Study: NCT02420613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02055794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing of the perineal skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closing perineal skin with surgical glue
Study: NCT02129647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Study: NCT02055794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No suturing of the perineal skin
Study: NCT03802318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rabeprazole
Description: Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
Study: NCT03989986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer Mentorship
Description: Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
Study: NCT03696966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Portion-Controlled Meals
Description: Increase dietary structure using portion-controlled meals (PCM)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Portion-Controlled Meals
Description: Increase dietary structure using portion-controlled meals (PCM)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-Calorie Diet
Description: Restrict calorie intake daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Very-Low Calorie Diet
Description: Severely restrict calorie intake intermittently
Study: NCT03410966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans cateheter ablation
Description: All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
Study: NCT03472807

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood sample or saliva
Description: at Inclusion

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood sample or saliva
Description: at Inclusion

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of a tumor sample taken before the participation of the patient in study
Description: at Inclusion

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood sample if tumor sample is not available
Description: at Inclusion
Study: NCT01368016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
Study: NCT03922334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.